摘要
近年来,抗血管生成药物成为治疗晚期非小细胞肺癌的新趋势,但仍存在毒副作用及耐药性等相关问题,而中药具有辨证论治及减毒增效的特点,其在晚期肺癌的治疗中发挥着不可替代的作用,日益受到医学各界的关注。本文通过回顾抗肿瘤血管生成药物单独或与其他治疗策略联合应用于非小细胞肺癌治疗的临床研究数据,试从不同角度,探讨非小细胞肺癌抗血管生成治疗的新思路。
Anti-angiogenic drugs have become a new trend in the treatment of advanced non-small cell lung cancer(NSCLC)in recent years,but there are still related problems,such as toxic side effects and drug resistance.TCM has the advantages of syndrome differentiation and attenuation and synergy,and it plays an irreplaceable role in the treatment of advanced lung cancer,therefore,it is receiving increasing attention from the field of medicine.This study reviewed the clinical research data of single anti-angiogenic drugs or combined with other treatment strategies in the treatment of NSCLC,trying to explore a new idea for treating the disease with anti-angiogenic therapy.
作者
倪萍
李泽庚
童佳兵
张星星
高雅婷
NI Ping;LI Zegeng;TONG Jiabing;ZHANG Xingxing;GAO Yating(Anhui University of Chinese Medicine,Hefei 230038,China;Institute of TCM Respiratory Diseases,Anhui Academy of Chinese Medical Science,Hefei 230031,China;The First Affiliated Hospitalof Anhui University of Chinese Medicine,Hefei 230031,China)
出处
《中医药学报》
CAS
2019年第6期125-130,共6页
Acta Chinese Medicine and Pharmacology
基金
国家自然科学基金面上项目(81874431,81804039)
安徽省自然科学基金项目(1808085QH256)
关键词
抗血管生成药物
中西医治疗
晚期非小细胞肺癌
Anti-angiogenic drugs
Integrated therapy of traditional Chinese and western medicine
Advanced non-small cell lung cancer
作者简介
倪萍(1993-),女,硕士研究生,研究方向:中医药防治呼吸系统疾病;通讯作者:李泽庚(1962-),男,主任医师,教授,博士生导师,研究方向:中医药防治呼吸系统疾病。
